Patents by Inventor Rajeevkumar Tawar

Rajeevkumar Tawar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-CLAUDIN-1 ANTIBODIES AND USES THEREOF
    Publication number: 20220411493
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 29, 2022
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas BAUMERT, Rajeevkumar Tawar
  • Humanized anti-claudin-1 antibodies and uses thereof
    Patent number: 11365251
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: June 21, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • BIFUNCTIONAL BINDING POLYPEPTIDES
    Publication number: 20210363216
    Abstract: The present invention provides bifunctional binding polypeptide comprising a pMHC binding moiety and a PD-1 agonist.
    Type: Application
    Filed: May 14, 2019
    Publication date: November 25, 2021
    Inventors: Giovanna BOSSI, Carlos REIS, Rajeevkumar TAWAR, Adam CURNOCK, Nicola SMITH
  • Humanized Anti-Claudin-1 Antibodies and Uses Thereof
    Publication number: 20210040204
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Humanized anti-claudin-1 antibodies and uses thereof
    Patent number: 10851160
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: December 1, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Chu Strasbourg, les Hopitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Humanized Anti-Claudin-1 Antibodies and Uses Thereof
    Publication number: 20190100586
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar